Drug · CHEMBL413
SIROLIMUS
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SIROLIMUS. Drugs and targets, record CHEMBL413. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL413
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
(-)-RAPAMYCIN, (-)-rapamycin, 23R*,26S*,27S*,34AR*]]-RAPAMYCIN, 25,26,27,32,33,34,34A-HEXADECAHYDRO-9,27-DIHYDROXY- 3-[2-(4-HYDROXY-3-METHOXYCYCLOHEXYL)-1-METHYLETHYL]- 10,21-DIMETHOXY-6,8,12,14,20,26-HEXAMETHYL-, 9,10,12,13,14,21,22,23,24, AY 22989, AY-22989, AY-22989,SIROLIMUS,WY-090217, FYARRO, Fyarro, HYFTOR, Hyftor, L04AA10, NPC-12G, NSC-226080, NSC-2260804, NSC-2260804,AY-22989, Npc-12g, RAPALIMUS, RAPAMUNE, RAPAMYCIN, RAPAMYCIN (AY-22989), RAPAMYCIN (SIROLIMUS), Rapalimus, Rapamycin, SIROLIMUS COMPONENT OF NAB-RAPAMYCIN RAPAMYCIN, SIROLIMUS COMPONENT OF SM-88, SIROLIMUSRAPAMUNERAPAMYCIN(-)-RAPAMYCINANTIBIOTIC AY 22989SIIA 9268AAY 22989WY 09021723,27-EPOXY-3H-PYRIDO[2,1-C][1,4]OXAAZACYCLOHENTRIACONTINE- 1,5,11,28,29(4H,6H,31H)-PENTONE, WY-090217, [3S-[3R*[S* (1R*,3S*,4S*)],6S*,7E,9S*,10S*,12S*,14R*,15E,17E,19E,21R*
- ChEMBL
- Open Targets' highest stage
- Approval, for 21 of its 262 diseases, from ATC, ClinicalTrials.gov, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | FK506-binding protein 1A inhibitor | INHIBITOR | https://conductscience.org/library/genes/2280 |
Source ChEMBL
Diseases262
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| type 1 diabetes mellitus | Phase 3 | ClinicalTrials.gov | 29 | 29 | https://conductscience.org/library/drugs?q=MONDO_0005147 |
| sickle cell disease | Phase 2 | ClinicalTrials.gov | 21 | 21 | https://conductscience.org/library/drugs?q=MONDO_0011382 |
| plasma cell myeloma | Approval | TTD | 15 | 14 | https://conductscience.org/library/drugs?q=MONDO_0009693 |
| acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 13 | 13 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
| acute myeloid leukemia | Phase 3 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0018874 |
| hematopoietic and lymphoid cell neoplasm | Phase 2 | ClinicalTrials.gov | 11 | 11 | https://conductscience.org/library/drugs?q=MONDO_0044881 |
| non-small cell lung carcinoma | Phase 1/2 | ClinicalTrials.gov | 11 | 11 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| graft versus host disease | Phase 2/3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0013730 |
| hepatocellular carcinoma | Phase 3 | ClinicalTrials.gov | 10 | 10 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
| tuberous sclerosis | Approval | EMA Human Drugs and PMDA | 11 | 9 | https://conductscience.org/library/drugs?q=MONDO_0001734 |
1 to 10 of 262Source Open Targets
See all 262 diseasesTrials692
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 9 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03468478 | Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation | Phase 4 | 1,209 | 2023-04-24 | sirolimus | Its name | ClinicalTrials.gov |
| NCT01120028 | Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy | Phase 2/3 | 852 | 2019-10-01 | sirolimus | Its name | ClinicalTrials.gov |
| NCT00038948 | Study Comparing Conversion to Sirolimus vs. Continued Use of Calcineurin Inhibitors in Kidney Transplant Recipients | Phase 3 | 830 | 2010-05-14 | sirolimus | Its name | ClinicalTrials.gov |
| NCT00086346 | Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients | Phase 3 | 607 | 2009-09-07 | sirolimus | Its name | ClinicalTrials.gov |
| NCT01062555 | Calcineurin Inhibitor Sparing After Kidney Transplantation | Phase 1/2 | 527 | 2020-12-14 | sirolimus | Its name | ClinicalTrials.gov |
| NCT00074490 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers | Phase 2 | 442 | 2018-12-31 | sirolimus | Its name | ClinicalTrials.gov |
| NCT03112603 | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) | Phase 3 | 330 | 2022-04-15 | sirolimus | Its name | ClinicalTrials.gov |
| NCT00121810 | Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients | Phase 4 | 305 | 2011-02-24 | sirolimus | Its name | ClinicalTrials.gov |
| NCT00406393 | Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | Phase 3 | 304 | 2016-03-07 | sirolimus | Its name | ClinicalTrials.gov |
| NCT00305682 | Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant | Phase 2 | 295 | 2020-11-02 | sirolimus | Its name | ClinicalTrials.gov |
1 to 10 of 692
See all 692 trialsComparisons in its trials166
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Period 1: Campath 1H/Tacrolimus vs Period 1: Basiliximab/Tacrolimus: Number of Participants With Serious Infection (at 6-months After Randomization to Induction Therapy) | 135 of 426 | 136 of 426 | 852 | NCT01120028 | Trial comparisons |
| Period 1: Alemtuzumab/Tacrolimus vs Period 1: Basiliximab/Tacrolimus: Number of Participants With Graft Failure (at 6-months After Randomization to Induction Therapy) | 16 of 426 | 13 of 426 | 852 | NCT01120028 | Trial comparisons |
| Period 1: Alemtuzumab/Tacrolimus vs Period 1: Basiliximab/Tacrolimus: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy | 31 of 426 | 68 of 426 | 852 | NCT01120028 | Trial comparisons |
| SRL Conversion in Stable Renal Transplant Recipients vs CNI Continuation in Stable Renal Transplant Recipients: serious adverse events | 81 of 551 | 45 of 273 | 824 | NCT00038948 | Trial comparisons |
| Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Major Vascular Event (at 18-months After Randomization to Maintenance Therapy) | 10 of 197 | 13 of 197 | 394 | NCT01120028 | Trial comparisons |
| Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Serious Infection (at 18-months After Randomization to Maintenance Therapy) | 95 of 197 | 70 of 197 | 394 | NCT01120028 | Trial comparisons |
| Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Cancer (at 18-months After Randomization to Maintenance Therapy) | 17 of 197 | 17 of 197 | 394 | NCT01120028 | Trial comparisons |
| Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Graft Failure (at 18-Months After Randomization to Maintenance Therapy) | 8 of 197 | 4 of 197 | 394 | NCT01120028 | Trial comparisons |
| Mycophenolate Mofetil + Sirolimus vs Mycophenolate Mofetil + Cyclosporine or Tacrolimus: serious adverse events | 60 of 148 | 64 of 153 | 301 | NCT00121810 | Trial comparisons |
| Tacrolimus/Sirolimus vs Tacrolimus/Methotrexate: serious adverse events | 9 of 149 | 12 of 152 | 301 | NCT00406393 | Trial comparisons |
1 to 10 of 166
See all 166 comparisons in its trialsPapers from its trials532
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials15
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Category Fluency | 2 | 1 | ConductCognition |
| Trail Making Test A | 2 | 0 | ConductCognition |
| Trail Making Test B | 2 | 0 | ConductCognition |
| Verbal Fluency | 2 | 0 | ConductCognition |
| Verbal Learning | 2 | 0 | ConductCognition |
| Dimensional Change Card Sort | 1 | 1 | ConductCognition |
| Clock Drawing Task | 1 | 0 | ConductCognition |
| Complex Figure Copy and Recall | 1 | 0 | ConductCognition |
| Design Fluency Test | 1 | 0 | ConductCognition |
| Digit Span Test | 1 | 1 | ConductCognition |
1 to 10 of 15
See all 15 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL413
GET https://conductscience.org/api/drugs/v1/CHEMBL413/diseases?page=2